Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Equity Ratio (2016 - 2025)

Ultragenyx Pharmaceutical has reported Equity Ratio over the past 11 years, most recently at 0.05 for Q4 2025.

  • Quarterly Equity Ratio fell 130.78% to 0.05 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.05 through Dec 2025, down 130.78% year-over-year, with the annual reading at 0.05 for FY2025, 130.78% down from the prior year.
  • Equity Ratio was 0.05 for Q4 2025 at Ultragenyx Pharmaceutical, down from 0.01 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.66 in Q1 2021 and troughed at 0.05 in Q4 2025.
  • The 5-year median for Equity Ratio is 0.2 (2023), against an average of 0.28.
  • Year-over-year, Equity Ratio skyrocketed 780.18% in 2024 and then tumbled 130.78% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.61 in 2021, then plummeted by 62.41% to 0.23 in 2022, then fell by 19.02% to 0.18 in 2023, then dropped by 8.01% to 0.17 in 2024, then tumbled by 130.78% to 0.05 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Equity Ratio are 0.05 (Q4 2025), 0.01 (Q3 2025), and 0.12 (Q2 2025).